Deals

Advanz and Alvotech have struck a deal that will give Advanz exclusive rights to the biosimilars developer’s Xolair (omalizumab) rival in multiple markets around the world.

Fresenius Kabi and Formycon have announced a global licensing deal for the FYB202 ustekinumab proposed biosimilar rival to Stelara. The deal comes as Formycon has revealed plans to raise further funds to funnel into research and development through a fresh share issue.

Ahead of wrapping up a Phase III clinical trial for its proposed biosimilar denosumab candidate later this year, mAbxience has out-licensed marketing rights in Korea to local player HK inno.N, with a patent expiry opportunity in 2025.

Sun has struck a $576m deal to acquire Concert Pharmaceuticals, picking up lead product candidate deuruxolitinib as part of an acquisition that advances the Indian firm’s specialty pivot.

Sandoz and Astellas have struck a deal that will see the Novartis subsidiary acquire global rights to the Mycamine micafungin antifungal brand, bolstering Sandoz’s anti-infectives portfolio and hospital offering.

Alvo group B2B unit Adalvo expects to file 30 decentralized procedures in Europe over the coming year as it expands its partnerships with Frontier Biopharma, Zentiva and Stada.

The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.

Teva has all but two US states on board for its long-hoped-for nationwide settlement to resolve opioid-related claims against the firm.

With a strategy to expand its reach across Asian markets, Natco Pharma has struck a distribution agreement with Zhongchao Inc.’s Xinjiang Pharmaceutical to sell select products in China.